Tokyo, Oct 3, 2005 (JCN) - Dainippon Sumitomo Pharma, a merged company of Dainippon Pharmaceutical and Sumitomo Pharmaceuticals, has launched its full-scale operations on October 1. The new company, which is headquartered in Osaka, has a capital of 22.4 billion yen and 5,150 employees on a non-consolidated base.
In a medium- and long-perspective, it aims to consolidate its presence in the field of diabetes and central nervous system disorders. The new company is the fifth-largest pharmaceutical company in Japan.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
 Company Profile |  Print |  Alerts
|
 |
|
Dainippon Sumitomo Pharma Opens Subsidiary in Singapore
(Jan 22, 2013)
|
|
|
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent
(Dec 28, 2012)
|
|
|
NOTICE of establishment of Drug Discovery Consortium in neuropsychiatric area
(Oct 23, 2008)
|
|
|
Dainippon Sumitomo, AstraZeneca to Develop Antiallergic Drug
(May 8, 2008)
|
|
|
Dainippon Sumitomo Pharma Review of Overseas Development of Lurasidone (SM-13496), an Atypical Antipsychotic
(Dec 13, 2006)
|
|
|
Dainippon Sumitomo Pharma Revises Domestic Development Plan of AC-5216, an Antianxiety/antidepressant Agent
(Nov 28, 2006)
|
|
|
Dainippon Sumitomo Pharma 2006 Annual Report to Shareholders, 'True Quality, Our New Beginning'
(Sept 21, 2006)
|
|
|
Dainippon Sumitomo Pharma 2006 Annual Report to Shareholders, 'True Quality, Our New Beginning'
(Sept 21, 2006)
|
|
|
Dainippon Sumitomo Pharma Enters into Partnership Agreement on Anti-Hypertension and Hepatocellular Cancer Drugs
(July 26, 2006)
|
|
|
Dainippon Sumitomo Pharma to Release AmBisome 50mg, Antifungal Agent for Deep-seated Mycosis Infection
(June 16, 2006)
|
|
|
